Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
66 Results for "
Flk
" in MedChemExpress (MCE) Product Catalog:
Products (66)
66 Results for "Flk" in MCE Product Catalog:
79
39
39 Cited Publications
Synonyms: PKC412; CGP 41251
Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .
7
Target:
Research Areas:
SU1498 (AG 1498) is a selective inhibitor of the VEGFR2; inhibits Flk-1 with an IC50 of value of 700 nM .
2
2 Cited Publications
Cat. No.: HY-P81643
Synonyms: KDR; Flk1; VEGFR2; Vascular endothelial growth factor receptor 2; VEGFR-2; Fetal liver kinase 1; Flk-1; Kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor Flk-1; CD antigen CD309
2
2 Cited Publications
Cat. No.: HY-P70178
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuReceptor-Type Tyrosine-Protein Kinase FLT3/FLT3, Fc; Receptor-Type Tyrosine-Protein Kinase FLT3; FL Cytokine Receptor; Fetal Liver Kinase-2; Flk-2; Fms-Like Tyrosine Kinase 3; FLT-3; Stem Cell Tyrosine Kinase 1; STK-1; CD135; FLT3; Flk2; STK1
1
1 Cited Publications
Cat. No.: HY-P1663
CAS No.: 272121-15-0
1
1 Cited Publications
Cat. No.: HY-P70552
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; Fetal liver kinase 1; Flk-1; Kinase insert domain receptor; Protein-tyrosine kinase receptor Flk-1; VEGFR2; VEGF R2
Synonyms: SU11654 phosphate; PHA 291639E phosphate
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .
Synonyms: SU11654; PHA 291639E
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .
SU4312 is the racemate of (Z)-SU4312 and (E)-SU4312. (Z)-SU4312 inhibits PDGFR and FLK-1 with IC50s of 19.4 and 0.8 μM, respectively. (E)-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC50s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively .
Cat. No.: HY-21291
CAS No.: 186611-55-2
SU-4313 is a potent protein tyrosine kinases (PTKs) modulator with IC50s of 14.5 μM, 18.8 μM, 11 μM, 16.9 μM, 8.0 μM for PDGFR, FLK-1, EGFR, HER2 Kinase and IGF-1R, respectively. SU-4313 has the potential for modulating tyrosine kinase signal transduction in order to regulate abnormal cell proliferation .
Synonyms: (Z)-SU6668; (Z)-TSU-68
(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors .
Synonyms: SU1433; AG1433
Tyrphostin AG1433 (SU1433) is a tyrosine kinases inhibitor. AG1433 is also a selective PDGFRβ and VEGFR-2 (Flk-1/KDR) inhibitor with IC50s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation .
BMS-605541 is a selective and orally active inhibitor of VEGFR-2 kinase with an IC50 value of 23 nM and Ki value of 49 nM. BMS-605541 inhibits the activity of Flk-1, VEGFR-1 and PDGFR-β with IC50 values of 40 nM, 400 nM and 200 nM, respectively. BMS-605541 can be used for cancer research .
Cat. No.: HY-148316
CAS No.: 186610-88-8
hVEGF-IN-2 (compound 19) is a selective VEGF (Flk-1) receptor tyrosine kinases (RTK) inhibitor with an IC50 value of 2.5 μM. hVEGF-IN-2 inhibits PDGF RTK activity with an IC50 value of 33.1 μM. hVEGF-IN-2 can be used for the development of RTK-specific agents .
Cat. No.: HY-10230S
Purity: ≥98.0%
Synonyms: PKC412-d5; CGP 41251-d5
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
